FindMyKOL
Clinical trialNCT03563222TerminatedPhase 4Interventional

Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age

NCT03563222 is a phase 4 interventional trial sponsored by Fresenius Kabi. As of 21 Nov 2026, it was terminated. It studies Intralipid, 20% and Smoflipid in Malnutrition, Child. The registry lists an enrollment of 1 participant at 1 site in 1 country. The registry lists a start date of 18 Dec 2019 and a primary completion date of 12 Nov 2020.

SponsorFresenius Kabi →Enrollment1Malnutrition, Child
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03563222
FieldValue
Registry IDNCT03563222
StatusTerminated
PhasePhase 4
Study typeInterventional trial
Lead sponsorFresenius Kabi
Enrollment1
Registered sites1
Countries1
ConditionsMalnutrition, Child
DrugsIntralipid, 20% and Smoflipid
Start18 Dec 2019
Primary completion12 Nov 2020
Study completion8 Jul 2022
Last update posted12 Dec 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Evaluate the safety and efficacy of Smoflipid compared to standard of care lipid emulsion Intralipid 20% administered via a central vein in pediatric patients 3 months to 16 years of age who require parenteral nutrition for at least 90 days and up to 1 year.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Pennsylvania, United States1 site
  • Children's Hospital of Pittsburgh of Upmc

    Pittsburgh

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Intralipid, 20%Smoflipid →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03563222

Each answer restates registry values shown on this page.

What is NCT03563222?

NCT03563222 is a phase 4 interventional trial sponsored by Fresenius Kabi. It studies Intralipid, 20% and Smoflipid in Malnutrition, Child.

Who leads NCT03563222?

The registry names Jeffrey Rudolph, MD (principal investigator, University of Pittsburgh) as the overall official.

Where does NCT03563222 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03563222 study?

The registered drug and biological interventions are Intralipid, 20% and Smoflipid.

When did NCT03563222 end?

The registry lists a primary completion date of 12 Nov 2020 and a study completion date of 8 Jul 2022. The sponsor last updated the record on 12 Dec 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.